These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

750 related articles for article (PubMed ID: 10654022)

  • 1. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction.
    Atta J; Fauth F; Keyser M; Petershofen E; Weber C; Lippok G; Hoelzer D; Martin H
    Bone Marrow Transplant; 2000 Jan; 25(1):97-104. PubMed ID: 10654022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Purging of peripheral blood stem cells yields BCR-ABL-negative autografts in patients with BCR-ABL-positive acute lymphoblastic leukemia.
    Martin H; Atta J; Zumpe P; Eder M; Elsner S; Rode C; Wassmann B; Bruecher J; Hoelzer D
    Exp Hematol; 1995 Dec; 23(14):1612-8. PubMed ID: 8542955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual leukemia and immunomagnetic bead purging in patients with BCR-ABL-positive acute lymphoblastic leukemia.
    Atta J; Martin H; Bruecher J; Elsner S; Wassmann B; Rode C; Russ A; Kvalheim G; Hoelzer D
    Bone Marrow Transplant; 1996 Sep; 18(3):541-8. PubMed ID: 8879615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymerase chain reaction: a method for monitoring tumor cell purge by long-term culture in BCR/ABL positive acute lymphoblastic leukemia.
    Fabrega S; Laporte JP; Giarratana MC; Douay L; Fouillard L; Da WM; Perrot C; Barbu V; Gorin NC
    Bone Marrow Transplant; 1993 Feb; 11(2):169-73. PubMed ID: 8435666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous BMT in high risk patients with CALLA-positive ALL: possible efficacy of ex vivo marrow leukemia cell purging with monoclonal antibodies and complement.
    Morishima Y; Miyamura K; Kojima S; Ueda R; Morishita Y; Sao H; Tanimoto M; Ohno R; Sobue R; Hirano M
    Bone Marrow Transplant; 1993 Apr; 11(4):255-9. PubMed ID: 7683550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia.
    Jándula BM; Nomdedeu J; Marín P; Vivancos P
    Bone Marrow Transplant; 2001 Jan; 27(2):225-7. PubMed ID: 11281397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission.
    De Rosa L; Lalle M; Pandolfi A; Ruscio C; Amodeo R
    Ann Hematol; 2002 Oct; 81(10):575-81. PubMed ID: 12424539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
    Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
    Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma.
    Leung W; Chen AR; Klann RC; Moss TJ; Davis JM; Noga SJ; Cohen KJ; Friedman AD; Small D; Schwartz CL; Borowitz MJ; Wharam MD; Paidas CN; Long CA; Karandish S; McMannis JD; Kastan MB; Civin CI
    Bone Marrow Transplant; 1998 Nov; 22(10):971-9. PubMed ID: 9849694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J; Wu B; Liu Q; Feng R; Liu X; Meng F; Zhou S
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug; 21(8):400-2. PubMed ID: 11877009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomagnetic bone marrow (BM) and peripheral blood progenitor cell (PBPC) purging in follicular lymphoma (FL).
    Martín-Henao GA; Picón M; Limón A; Carmona M; Amill B; Azqueta C; López R; González-Barca E; Grañena A; Brunet S; García J
    Bone Marrow Transplant; 1999 Mar; 23(6):579-87. PubMed ID: 10217189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficiency of tumor cell purging using immunomagnetic CD34+ cell separation systems.
    Roots-Weiss A; Papadimitriou C; Serve H; Hoppe B; Koenigsmann M; Reufi B; Oberberg D; Thiel E; Berdel WE
    Bone Marrow Transplant; 1997 Jun; 19(12):1239-46. PubMed ID: 9208119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD34(+) hematopoietic progenitor cell selection of bone marrow grafts for autologous transplantation in pediatric patients.
    Kasow KA; Sims-Poston L; Eldridge P; Hale GA
    Biol Blood Marrow Transplant; 2007 May; 13(5):608-14. PubMed ID: 17448921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purging and haemopoietic progenitor cell selection by CD34+ cell separation.
    Krüger W; Gruber M; Hennings S; Fehse N; Fehse B; Gutensohn K; Kröger N; Zander AR
    Bone Marrow Transplant; 1998 Apr; 21(7):665-71. PubMed ID: 9578305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement.
    Grañena A; Castellsagué X; Badell I; Ferra C; Ortega J; Brunet S; Puntí C; Sureda A; Picón M; Valls A; Rutllant M; García J
    Bone Marrow Transplant; 1999 Sep; 24(6):621-7. PubMed ID: 10490727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sequential analysis of p210- and p190-bcr-abl by RT-PCR after allogeneic bone marrow transplantation for p210/p190-bcr-abl double positive acute lymphoblastic leukemia].
    Fujimaki K; Maruta A; Yoshida M; Yamazaki E; Motomura S; Kodama F; Matsuzaki M; Fujisawa S; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2001 Feb; 42(2):89-93. PubMed ID: 11280922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Matsue K; Tabayashi T; Yamada K; Takeuchi M
    Bone Marrow Transplant; 2002 Jan; 29(1):63-6. PubMed ID: 11840146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infusion of tumor-contaminated bone marrow for autologous rescue after high-dose therapy leading to long-term remission in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Peters SO; Stockschläder M; Hegewisch-Becker S; Krüger W; Weh HJ; Hossfeld DK; Zander AR
    Bone Marrow Transplant; 1995 May; 15(5):783-4. PubMed ID: 7670406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of minimal residual disease in patients with childhood common acute lymphoblastic leukemia after autologous bone marrow transplantation with ex vivo purging and systemic IL-2 infusion: unsuccessful prediction of subsequent relapse.
    Kiyoi H; Kojima S; Kato K; Matsuyama T; Kodera Y; Ohno R; Naoe T
    Bone Marrow Transplant; 1995 Sep; 16(3):437-42. PubMed ID: 8535317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.